Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Long-term follow-up of renal function in patients treated with migalastat for Fabry disease

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Incidence of Aicardi-Goutières syndrome and KCNT1-related epilepsy in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Hearing loss in fabry disease: A 16 year follow-up study of the Danish nationwide cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Case report: ‘AARS2 leukodystrophy’

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Daniel G Bichet
  • Roser Torra
  • Eric Wallace
  • Derralynn Hughes
  • Roberto Giugliani
  • Nina Skuban
  • Eva Krusinska
  • Ulla Feldt-Rasmussen
  • Raphael Schiffmann
  • Kathy Nicholls
View graph of relations

The effect of migalastat on long-term renal outcomes in enzyme replacement therapy (ERT)-naive and ERT-experienced patients with Fabry disease is not well defined. An integrated posthoc analysis of the phase 3 clinical trials and open-label extension studies was conducted to evaluate long-term changes in renal function in patients with Fabry disease and amenable GLA variants who were treated with migalastat for ≥2 years during these studies. The analysis included ERT-naive (n = 36 [23 females]; mean age 45 years; mean baseline estimated glomerular filtration rate (eGFR), 91.4 mL/min/mL/1.73 m2) and ERT-experienced (n = 42 [24 females]; mean age, 50 years; mean baseline eGFR, 89.2 mL/min/1.73m2) patients with amenable variants who received migalastat 123 mg every other day for ≥2 years. The annualized rate of change from baseline to last observation in estimated glomerular filtration rate using the Chronic Kidney Disease Epidemiology Collaboration equation (eGFRCKD-EPI) was calculated by both simple linear regression and a random coefficient model. In ERT-naive patients, mean annualized rates of change from baseline in eGFRCKD-EPI were - 1.6 mL/min/1.73 m2 overall and - 1.8 mL/min/1.73 m2 and - 1.4 mL/min/1.73 m2 in male and female patients, respectively, as estimated by simple linear regression. In ERT-experienced patients, mean annualized rates of change from baseline in eGFRCKD-EPI were - 1.6 mL/min/1.73 m2 overall and - 2.6 mL/min/1.73 m2 and - 0.8 mL/min/1.73 m2 in male and female patients, respectively. Mean annualized rate of change in eGFRCKD-EPI in ERT-naive patients with the classic phenotype (defined by white blood cell alpha galactosidase A [α-Gal A] activity of <3% of normal and multiorgan system involvement) was -1.7 mL/min/1.73 m2. When calculated using the random coefficient model, which adjusted for sex, age, and baseline renal function, the annualized eGFRCKD-EPI change was minimal (mean: -0.1 and 0.1 mL/min/1.73 m2 in ERT-naive and ERT-experienced patients, respectively). In conclusion, patients with Fabry disease and amenable GLA variants receiving long-term migalastat treatment (≤8.6 years) maintained renal function irrespective of treatment status, sex, or phenotype.

Original languageEnglish
Article number100786
JournalMolecular Genetics and Metabolism Reports
Volume28
Pages (from-to)100786
ISSN2214-4269
DOIs
Publication statusPublished - Sep 2021

Bibliographical note

© 2021 The Authors. Published by Elsevier Inc.

ID: 74274105